health · digital · family: the rulebook was written for a world that no longer exists
locked into one brand's pancreas
Why can't diabetes patients mix and match their insulin pump, CGM, and algorithm?
Problem statement
Automated insulin delivery (AID) systems combine continuous glucose monitors (CGMs), insulin pumps, and control algorithms into a closed loop — but each commercial system is limited to specific combinations of the three. A patient cannot pair a CGM from one company with a pump from another and an algorithm from a third, even when each component is individually FDA-cleared. The FDA created "interoperability designations" (iCGM, ACE pump) intended to enable mix-and-match, but every cleared AID algorithm still works with only one pump manufacturer's hardware. This vendor lock-in limits patient choice and leaves third-party algorithm developers who lack pump hardware dependent on a pump manufacturer to reach the market.
Why this matters
AID systems are becoming established in both Type 1 and Type 2 diabetes. A patient who wants one manufacturer's pump with a control algorithm supplied by a different pump manufacturer cannot get that combination, and each pump works only with the CGMs it has been integrated with. An FDA-cleared algorithm from a developer that makes no pump reaches patients only if a pump manufacturer adopts it. The source article notes that one algorithm, CamAPS FX, is cleared by the FDA but runs on no FDA-approved pump in the United States.
What’s been tried and why it hasn’t worked
The FDA's iCGM and ACE pump designations were designed to create interoperable component classes, but no pump manufacturer yet markets an AID system that offers a choice of more than one algorithm. The source article names regulatory, technological, and commercial barriers: each added algorithm needs its own FDA clearance or rights acquired from its developer, a pump that runs several algorithms is more complex to build and support, and pump manufacturers see little consumer demand so far. Tidepool Loop, an iPhone app from developers who make no insulin pump, received FDA clearance in 2023. In March 2024 the startup pump company Sequel announced FDA clearance for a new AID system that will incorporate the Tidepool Loop algorithm. The Abbott-Medtronic partnership (August 2024) to integrate their CGM and pump shows integration being arranged through a commercial agreement between two companies: Abbott will supply a CGM that works exclusively with Medtronic's devices.
What would unlock progress
A standardized communication protocol and safety verification framework for AID components — analogous to USB or Bluetooth in consumer electronics — would allow any cleared algorithm to operate on any ACE pump with any iCGM. Solving the combinatorial testing problem (validating N x M component pairings without testing every combination) and establishing clear liability assignment for multi-manufacturer system failures would remove two more barriers.
Entry points for student teams
A student team could prototype a middleware layer that translates between the proprietary communication protocols of existing CGMs and pumps, demonstrating feasibility on bench hardware. Alternatively, a team could develop a simulation-based safety verification framework that characterizes algorithm-pump interaction safety without requiring physical testing of every combination. Mapping the current regulatory pathway gaps and proposing a concrete standards roadmap would also be a valuable design-research contribution.
Genes
Tags marked “under review” were questioned by a later calibration pass; they stay visible here but are left out of filters until re-adjudicated.
Structural cousins: stuck the same way, in other fields
Sources
FDA, "Types of Artificial Pancreas Device Systems," Klonoff DC, Ho CN, Ayers A, Abdel-Malek A, "FDA Interoperability Designation—Creating Options for People With Diabetes and Pump Companies: Regulatory, Technological, and Commercial Perspectives," Journal of Diabetes Science and Technology 19(4):869–874 (published online 2024-09-10), accessed 2026-02-19 go to source 1 ↗ go to source 2 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
Primary sources are FDA CDRH documentation and peer-reviewed diabetes technology literature. The interoperability failure parallels problems in other device ecosystems where component-level clearance does not produce system-level compatibility (cf. EHR interoperability). The coordination constraint is the dominant gene — technical feasibility has been demonstrated by the DIY community, but regulatory and commercial structures prevent adoption. Related brief: health-device-cybersecurity-postmarket (shared concern about connected medical device ecosystems).
Reconciliation 2026-09-29: A site review read this whole write-up against both sources it cites. The FDA page was fetched in full on 2026-09-29 from https://www.fda.gov/medical-devices/artificial-pancreas-device-system/types-artificial-pancreas-device-systems. The publisher's page for the journal article refused automated access, so the same article was read in full on 2026-09-29 from its PubMed Central copy at https://pmc.ncbi.nlm.nih.gov/articles/PMC11571429/, and its citation record was fetched from https://api.crossref.org/works/10.1177/19322968241271304. The FDA page says its content is current as of December 17, 2017. It describes three types of artificial pancreas system and does not mention interoperability, so the specific claims here rest on the journal article. (1) The text said "approximately 1.9 million Americans with Type 1 diabetes are candidates for AID systems." Neither source gives this number or any count of patients. It was removed. The article says AID products are becoming established in both type 1 and type 2 diabetes, and the sentence now says that. (2) The text said each system "is locked into a single manufacturer's ecosystem." The article's Table 3 lists six FDA-approved systems, and four of them combine a pump from one company with a CGM from another (Dexcom or Abbott). What the article says is that each cleared algorithm is found on a single manufacturer's pump and each pump offers a single algorithm. The sentence now says systems are limited to specific combinations. (3) The text said lock-in forces patients to replace their entire system when one component is recalled or discontinued, stops them choosing the most accurate CGM, creates supply chain fragility, and reduces innovation pressure. None of these is in either source. They were replaced with what the article reports, including that the CamAPS FX algorithm is cleared but runs on no FDA-approved pump in the United States. (4) The text said the designations failed "because no standardized communication protocol, data format, or safety verification framework exists." The article does not say this. It names regulatory, technological and commercial barriers, and the sentence now lists those. (5) The text said Tidepool Loop "remains commercially unavailable because no pump manufacturer has obtained the separate FDA clearance needed." The article says the opposite about clearance: it lists five cleared ACE pumps, and it reports that Sequel announced FDA clearance on March 18, 2024 for a system that will incorporate Tidepool Loop. The sentence now reports that. The article does not call Tidepool Loop open-source, so that word was removed. (6) The text said the Abbott-Medtronic partnership shows interoperability "requires bilateral commercial agreements rather than open standards." The article reports the partnership and says the Abbott CGM will work exclusively with Medtronic's devices. It does not discuss open standards. The sentence now follows the article. (7) The sentence about the DIY community (Loop, OpenAPS, AndroidAPS) was removed because neither source discusses it. The article only lists a consensus statement on open-source systems among its references. (8) "The two deepest structural barriers" now reads "two more barriers," because the article does not discuss testing of component pairings or liability and does not rank barriers. (9) The Source line gave a shortened title with no authors. It now carries the authors, full title, volume, issue and pages copied from the fetched record. The link is unchanged. Confirmed against the article and left as written: the iCGM and ACE pump designations and their purpose; that every cleared algorithm works with one pump manufacturer's hardware; FDA clearance of Tidepool Loop in 2023 (January 24, 2023); the Abbott-Medtronic announcement in August 2024 (August 7, 2024); the title of the FDA page. NOT sourced: the section on what would unlock progress is this write-up's own proposal. The article does not discuss a shared communication protocol, the comparison to USB or Bluetooth, or liability. The working note above that says the DIY community has shown technical feasibility, and the comparison to health record systems, are also not from the cited sources. Genes untouched.